-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Initiates Coverage On BridgeBio Oncology with Outperform Rating, Announces Price Target of $25

Benzinga·09/17/2025 12:21:49
Listen to the news
Leerink Partners analyst Andrew Berens initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Outperform rating and announces Price Target of $25.